Non-selective beta-blocker is associated with reduced mortality in critically ill patients with cirrhosis: A real-world study.
Rahul KumarSu LinGautam MehtaMonica D MesquitaJoana A F CalvaoM Faisal SheikhBanwari AgarwalRajeshwar Prosad MookerjeeMohsin Faysal ButtPublished in: Alimentary pharmacology & therapeutics (2024)
Prior use of NSBB is associated with improved 28- and 90-day mortality in critically ill cirrhosis patients with AD which is mediated probably by blunting of the inflammatory response.